D’souza A.A.; Shegokar R.; Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv 2016,13(9),1257-1275
[DOI:
10.1080/17425247.2016.1182485]
Abuchowski A.; van Es T.; Palczuk N.C.; Davis F.F.; Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977,252(11),3578-3581
[DOI:
10.1016/S0021-9258(17)40291-2]
Yamaoka T.; Tabata Y.; Ikada Y.; Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994,83(4),601-606
[DOI:
10.1002/jps.2600830432]
Monfardini C.; Schiavon O.; Caliceti P.; Morpurgo M.; Harris J.M.; Veronese F.M.; A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995,6(1),62-69
[DOI:
10.1021/bc00031a006]
Harris J.M.; Chess R.B.; Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003,2(3),214-221
[DOI:
10.1038/nrd1033]
Israelachvili J.; The different faces of poly(ethylene glycol). Proc Natl Acad Sci USA 1997,94(16),8378-8379
[DOI:
10.1073/pnas.94.16.8378]
Awad N.S.; Paul V.; Mahmoud M.S.; Al Sawaftah N.M.; Kawak P.S.; Al Sayah M.H.; Husseini G.A.; Effect of pegylation and targeting moieties on the ultrasound-mediated drug release from liposomes. ACS Biomater Sci Eng 2020,6(1),48-57
[DOI:
10.1021/acsbiomaterials.8b01301]
Haghiralsadat F.; Amoabediny G.; Helder M.N.; Naderinezhad S.; Sheikhha M.H.; Forouzanfar T.; Zandieh-doulabi B.; A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery. Artif Cells Nanomed Biotechnol 2018,46(1),169-177
[DOI:
10.1080/21691401.2017.1304403]
Mishra P.; Nayak B.; Dey R.K.; PEGylation in anti-cancer therapy: An overview. Asian J Pharm Sci 2016,11(3),337-348
[DOI:
10.1016/j.ajps.2015.08.011]
Abuchowski A.; Kazo G.M.; Verhoest C.R.; Van Es T.; Kafkewitz D.; Nucci M.L.; Viau A.T.; Davis F.F.; Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984,7(2),175-186
[PMID:
6467175]
Hershfield M.S.; Buckley R.H.; Greenberg M.L.; Melton A.L.; Schiff R.; Hatem C.; Kurtzberg J.; Markert M.L.; Kobayashi R.H.; Kobayashi A.L.; Abuchowski A.; Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987,316(10),589-596
[DOI:
10.1056/NEJM198703053161005]
Li W.; Zhan P.; De Clercq E.; Lou H.; Liu X.; Current drug research on PEGylation with small molecular agents. Prog Polym Sci 2013,38(3-4),421-444
[DOI:
10.1016/j.progpolymsci.2012.07.006]
Park E.J.; Choi J.; Lee K.C.; Na D.H.; Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs 2019,24(2),107-119
[DOI:
10.1080/14728214.2019.1604684]
Asano S.; Gavrilyuk J.; Burton D.R.; Barbas C.F.; III Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc. ACS Med Chem Lett 2014,5(2),133-137
[DOI:
10.1021/ml400370w]
Xiao Q.; Bécar N.A.; Brown N.P.; Smith M.S.; Stern K.L.; Draper S.R.E.; Thompson K.P.; Price J.L.; Stapling of two PEGylated side chains increases the conformational stability of the WW domain via an entropic effect. Org Biomol Chem 2018,16(46),8933-8939
[DOI:
10.1039/C8OB02535E]
Verma P.; Dayal S.; Jain V.K.; Amrani A.; Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: A rare case report. J Chemother 2017,29(6),380-382
[DOI:
10.1080/1120009X.2016.1245235]
Knauf M.J.; Bell D.P.; Hirtzer P.; Luo Z.P.; Young J.D.; Katre N.V.; Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 1988,263(29),15064-15070
[DOI:
10.1016/S0021-9258(18)68146-3]
Caliceti P.; Veronese F.M.; Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Adv Drug Deliv Rev 2003,55(10),1261-1277
[DOI:
10.1016/S0169-409X(03)00108-X]
Fu M.; Zhuang X.; Zhang T.; Guan Y.; Meng Q.; Zhang Y.; PEGylated leuprolide with improved pharmacokinetic properties. Bioorg Med Chem 2020,28(4),115306
[DOI:
10.1016/j.bmc.2020.115306]
Katre N.V.; The conjugation of proteins with polyethylene glycol and other polymers. Adv Drug Deliv Rev 1993,10(1),91-114
[DOI:
10.1016/0169-409X(93)90005-O]
Zhou J.Q.; He T.; Wang J.W.; PEGylation of cytochrome c at the level of lysine residues mediated by a microbial transglutaminase. Biotechnol Lett 2016,38(7),1121-1129
[DOI:
10.1007/s10529-016-2083-6]
da Silva Freitas D.; Mero A.; Pasut G.; Chemical and enzymatic site specific PEGylation of hGH. Bioconjug Chem 2013,24(3),456-463
[DOI:
10.1021/bc300594y]
Gonzلlez-Valdez J.; Cueto L.F.; Benavides J.; Rito-Palomares M.; Potential application of aqueous two-phase systems for the fractionation of RNase A and α-Lactalbumin from their PEGylated conjugates. J Chem Technol Biotechnol 2011,86(1),26-33
[DOI:
10.1002/jctb.2507]
Pasut G.; Veronese F.M.; State of the art in PEGylation: The great versatility achieved after forty years of research. J Control Release 2012,161(2),461-472
[DOI:
10.1016/j.jconrel.2011.10.037]
Rajender Reddy K.; Modi M.W.; Pedder S.; Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002,54(4),571-586
[DOI:
10.1016/S0169-409X(02)00028-5]
Foser S.; Schacher A.; Weyer K.A.; Brugger D.; Dietel E.; Marti S.; Schreitmüller T.; Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS). Protein Expr Purif 2003,30(1),78-87
[DOI:
10.1016/S1046-5928(03)00055-X]
Grigoletto A.; Mero A.; Zanusso I.; Schiavon O.; Pasut G.; Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG- N -Terminal-hGH and PEG-Gln141-hGH Conjugates. Macromol Biosci 2016,16(1),50-56
[DOI:
10.1002/mabi.201500282]
Luo S.; Lu X.; Liu C.; Zhong J.; Zhou L.; Chen T.; Site specific PEGylation of β-lactoglobulin at glutamine residues and its influence on conformation and antigenicity. Food Res Int 2019,123,623-630
[DOI:
10.1016/j.foodres.2019.05.038]
Molineux G.; The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004,10(11),1235-1244
[DOI:
10.2174/1381612043452613]
Singh M.; Salnikova M.; Novel approaches and strategies for biologics, vaccines and cancer therapies 2015
Wang Y.; Langley R.J.; Tamshen K.; Harms J.; Middleditch M.J.; Maynard H.D.; Jamieson S.M.F.; Perry J.K.; Enhanced bioactivity of a human GHR antagonist generated by solid-phase site-specific PEGylation. Biomacromolecules 2021,22(2),299-308
[DOI:
10.1021/acs.biomac.0c01105]
Roberts M.J.; Bentley M.D.; Harris J.M.; Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002,54(4),459-476
[DOI:
10.1016/S0169-409X(02)00022-4]
Veronese F.M.; Caliceti P.; Schiavon O.; Branched and linear Poly(Ethylene Glycol): Influence of the Polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Compat Polym 1997,12(3),196-207
[DOI:
10.1177/088391159701200303]
Gokarn Y.R.; McLean M.; Laue T.M.; Effect of PEGylation on protein hydrodynamics. Mol Pharm 2012,9(4),762-773
[DOI:
10.1021/mp200470c]
Constantinou A.; Chen C.; Deonarain M.P.; Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett 2010,32(5),609-622
[DOI:
10.1007/s10529-010-0214-z]
Kim J.; Kong Y.P.; Niedzielski S.M.; Singh R.K.; Putnam A.J.; Shikanov A.; Characterization of the crosslinking kinetics of multi-arm poly(ethylene glycol) hydrogels formed via Michael-type addition. Soft Matter 2016,12(7),2076-2085
[DOI:
10.1039/C5SM02668G]
Adkins C.E.; Nounou M.I.; Hye T.; Mohammad A.S.; Terrell-Hall T.; Mohan N.K.; Eldon M.A.; Hoch U.; Lockman P.R.; NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 2015,15(1),685
[DOI:
10.1186/s12885-015-1672-4]
Garrett C.R.; Bekaii-Saab T.S.; Ryan T.; Fisher G.A.; Clive S.; Kavan P.; Shacham-Shmueli E.; Buchbinder A.; Goldberg R.M.; Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer 2013,119(24),4223-4230
[DOI:
10.1002/cncr.28358]
Charych D.H.; Hoch U.; Langowski J.L.; Lee S.R.; Addepalli M.K.; Kirk P.B.; Sheng D.; Liu X.; Sims P.W.; VanderVeen L.A.; Ali C.F.; Chang T.K.; Konakova M.; Pena R.L.; Kanhere R.S.; Kirksey Y.M.; Ji C.; Wang Y.; Huang J.; Sweeney T.D.; Kantak S.S.; Doberstein S.K.; NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res 2016,22(3),680-690
[DOI:
10.1158/1078-0432.CCR-15-1631]
Zalipsky S.; Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem 1995,6(2),150-165
[DOI:
10.1021/bc00032a002]
Zalipsky S.; Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev 1995,16(2-3),157-182
[DOI:
10.1016/0169-409X(95)00023-Z]
Harris J.M.; Laboratory synthesis of polyethylene glycol derivatives. J Macromol Sci 1985,25(3),325-373
Dust J.M.; Fang Z.H.; Harris J.M.; Proton NMR characterization of poly(ethylene glycols) and derivatives. Macromolecules 1990,23(16),3742-3746
[DOI:
10.1021/ma00218a005]
A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2A (PEGIFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) Available From: https://www.natap.org/2000/7thcroi/37rpt22300.html1999
Bailon P.; Palleroni A.; Schaffer C.A.; Spence C.L.; Fung W.J.; Porter J.E.; Ehrlich G.K.; Pan W.; Xu Z.X.; Modi M.W.; Farid A.; Berthold W.; Graves M.; Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem 2001,12(2),195-202
[DOI:
10.1021/bc000082g]
Swierczewska M.; Lee K.C.; Lee S.; What is the future of PEGylated therapies? Expert Opin Emerg Drugs 2015,20(4),531-536
[DOI:
10.1517/14728214.2015.1113254]
Metelsky S.T.; Dependence of the apparent thickness of the unstirred layer at the intestinal mucosa on nutrient concentration. Biophysics 2007,52(4),423-425
[DOI:
10.1134/S0006350907040124]
Madonov P.G.; Svyatchenko V.A.; Legostaev S.S.; Kikhtenko N.A.; Kotlyarova A.A.; Oleinik L.A.; Baikalov G.I.; Evaluation of the anti-viral activity of human recombinant interferon Lambda-1 against SARS-CoV-2. Bull Exp Biol Med 2021,172(1),53-56
[DOI:
10.1007/s10517-021-05330-0]
Sherstoboev E.Y.; Oleinik L.A.; Zhdanov V.V.; Kikhtenko N.A.; Madonov P.G.; Pharmacokinetic parameters of oral Pegylated IFN-λ1. Bull Exp Biol Med 2022,173(2),215-218
[DOI:
10.1007/s10517-022-05521-3]
Chan K.; Mong M.; Yin M.; Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci 2009,74(7),H225-H231
[DOI:
10.1111/j.1750-3841.2009.01274.x]
Park J.H.; Yeo I.J.; Han J.H.; Suh J.W.; Lee H.P.; Hong J.T.; Anti-inflammatory effect of astaxanthin in phthalic anhydride-induced atopic dermatitis animal model. Exp Dermatol 2018,27(4),378-385
[DOI:
10.1111/exd.13437]
Maoka T.; Tokuda H.; Suzuki N.; Kato H.; Etoh H.; Anti-oxidative, anti-tumor-promoting, and anti-carcinogensis activities of nitroastaxanthin and nitrolutein, the reaction products of astaxanthin and lutein with peroxynitrite. Mar Drugs 2012,10(12),1391-1399
[DOI:
10.3390/md10061391]
Zhang L.; Wang H.; Multiple mechanisms of anti-cancer effects exerted by Astaxanthin. Mar Drugs 2015,13(7),4310-4330
[DOI:
10.3390/md13074310]
Takemoto M.; Yamaga M.; Furuichi Y.; Yokote K.; Astaxanthin improves nonalcoholic fatty liver disease in werner syndrome with diabetes mellitus. J Am Geriatr Soc 2015,63(6),1271-1273
[DOI:
10.1111/jgs.13505]
Sifi N.; Martin-Eauclaire M.F.; Laraba-Djebari F.K.; + channel blocker-induced neuroinflammatory response and neurological disorders: Immunomodulatory effects of astaxanthin. Inflamm Res 2016,65(8),623-634
[DOI:
10.1007/s00011-016-0945-y]
Li Y.; Kang T.; Wu Y.; Chen Y.; Zhu J.; Gou M.; Carbonate esters turn camptothecin-unsaturated fatty acid prodrugs into nanomedicines for cancer therapy. Chem Commun 2018,54(16),1996-1999
[DOI:
10.1039/C8CC00639C]
Liu Y.; Yang L.; Guo Y.; Zhang T.; Qiao X.; Wang J.; Xu J.; Xue C.; Hydrophilic Astaxanthin: PEGylated Astaxanthin fights diabetes by enhancing the solubility and oral absorbability. J Agric Food Chem 2020,68(11),3649-3655
[DOI:
10.1021/acs.jafc.0c00784]
Kouchakzadeh H.; Shojaosadati S.A.; Maghsoudi A.; Vasheghani Farahani E.; Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS PharmSciTech 2010,11(3),1206-1211
[DOI:
10.1208/s12249-010-9487-8]
Zhang X.; Pan S.R.; Hu H.M.; Wu G.F.; Feng M.; Zhang W.; Luo X.; Poly(ethylene glycol)-block-polyethylenimine copolymers as carriers for gene delivery: Effects of PEG molecular weight and PEGylation degree. J Biomed Mater Res A 2008,84A(3),795-804
[DOI:
10.1002/jbm.a.31343]
Tahmasbi Rad A.; Chen C.W.; Aresh W.; Xia Y.; Lai P.S.; Nieh M.P.; Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers. ACS Appl Mater Interfaces 2019,11(11),10505-10519
[DOI:
10.1021/acsami.8b21609]
Yoshikawa T.; Mori Y.; Feng H.; Phan K.Q.; Kishimura A.; Kang J.H.; Mori T.; Katayama Y.; Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect. Int J Pharm 2019,565,481-487
[DOI:
10.1016/j.ijpharm.2019.05.043]
Ming L.J.; Epperson J.D.; Metal binding and structure–activity relationship of the metalloantibiotic peptide bacitracin. J Inorg Biochem 2002,91(1),46-58
[DOI:
10.1016/S0162-0134(02)00464-6]
Smith J.L.; Weinberg E.D.; Mechanisms of antibacterial action of bacitracin. J Gen Microbiol 1962,28(3),559-569
[DOI:
10.1099/00221287-28-3-559]
Hancock R.; Fitz-James P.C.; Some differences in the action of penicillin, bacitracin, and vancomycin on Bacillus megaterium. J Bacteriol 1964,87(5),1044-1050
[DOI:
10.1128/jb.87.5.1044-1050.1964]
Hong W.; Gao X.; Qiu P.; Yang J.; Qiao M.; Shi H.; Zhang D.; Tian C.; Niu S.; Liu M.; Synthesis, construction, and evaluation of self-assembled nano-bacitracin A as an efficient antibacterial agent in vitro and in vivo. Int J Nanomedicine 2017,12,4691-4708
[DOI:
10.2147/IJN.S136998]
Hong W.; Zhao Y.; Guo Y.; Huang C.; Qiu P.; Zhu J.; Chu C.; Shi H.; Liu M.; PEGylated self-assembled nano-bacitracin A: Probing the antibacterial mechanism and real-time tracing of target delivery in vivo. ACS Appl Mater Interfaces 2018,10(13),10688-10705
[DOI:
10.1021/acsami.8b00135]
Soe Z.C.; Ou W.; Gautam M.; Poudel K.; Kim B.K.; Pham L.M.; Phung C.D.; Jeong J.H.; Jin S.G.; Choi H.G.; Ku S.K.; Yong C.S.; Kim J.O.; Development of folate-functionalized pegylated zein nanoparticles for ligand-directed delivery of paclitaxel. Pharmaceutics 2019,11(11),562
[DOI:
10.3390/pharmaceutics11110562]
Zeng N.; Hu Q.; Liu Z.; Gao X.; Hu R.; Song Q.; Gu G.; Xia H.; Yao L.; Pang Z.; Jiang X.; Chen J.; Fang L.; Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm 2012,424(1-2),58-66
[DOI:
10.1016/j.ijpharm.2011.12.058]
Phung C.D.; Tran T.H.; Kim J.O.; Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: A review. Arch Pharm Res 2020,43(1),32-45
[DOI:
10.1007/s12272-020-01218-1]
Cho H.J.; Recent progresses in the development of hyaluronic acid-based nanosystems for tumor-targeted drug delivery and cancer imaging. J Pharm Investig 2020,50(2),115-129
[DOI:
10.1007/s40005-019-00448-w]
Tran B.N.; Nguyen H.T.; Kim J.O.; Yong C.S.; Nguyen C.N.; Developing combination of artesunate with paclitaxel loaded into poly- D,L -lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response. Drug Dev Ind Pharm 2017,43(12),1952-1962
[DOI:
10.1080/03639045.2017.1357729]
Aung W.; Sogawa C.; Furukawa T.; Saga T.; Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res 2011,31(5),1549-1558
[PMID:
21617209]
Chen Y.; Chin B.W.; Bieber M.M.; Tan X.; Teng N.N.; Abstract 470: Artemisinin derivatives synergize with paclitaxel by targeting FOXM1 through Raf/MEK/MAPK signaling pathway in ovarian cancer. Cancer Res 2014,74,470-470
[DOI:
10.1158/1538-7445.AM2014-470]
Wang L.; Wang Y.; Wang X.; Sun L.; Zhou Z.; Lu J.; Zheng Y.; Encapsulation of low lipophilic and slightly water-soluble dihydroartemisinin in PLGA nanoparticles with phospholipid to enhance encapsulation efficiency and in vitro bioactivity. J Microencapsul 2016,33(1),43-52
[DOI:
10.3109/02652048.2015.1114042]
Phung C.D.; Le T.G.; Nguyen V.H.; Vu T.T.; Nguyen H.Q.; Kim J.O.; Yong C.S.; Nguyen C.N.; PEGylated-Paclitaxel and dihydroartemisinin nanoparticles for simultaneously delivering paclitaxel and dihydroartemisinin to colorectal cancer. Pharm Res 2020,37(7),129
[DOI:
10.1007/s11095-020-02819-7]
Chen X.; Mangala L.S.; Rodriguez-Aguayo C.; Kong X.; Lopez-Berestein G.; Sood A.K.; RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 2018,37(1),107-124
[DOI:
10.1007/s10555-017-9717-6]
Hatakeyama H.; Akita H.; Harashima H.; The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull 2013,36(6),892-899
[DOI:
10.1248/bpb.b13-00059]
Hattori Y.; Tamaki K.; Sakasai S.; Ozaki K.I.; Onishi H.; Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene silencing effects and siRNA biodistribution in mice. Mol Med Rep 2020,22(5),4183-4196
[DOI:
10.3892/mmr.2020.11525]
Zhang X.; Wang H.; Ma Z.; Wu B.; Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol 2014,10(12),1691-1702
[DOI:
10.1517/17425255.2014.967679]
Hoguet V.; Lasalle M.; Maingot M.; Dequirez G.; Boulahjar R.; Leroux F.; Piveteau C.; Herledan A.; Biela A.; Dumont J.; Chلvez-Talavera O.; Belloy L.; Duplan I.; Hennuyer N.; Butruille L.; Lestavel S.; Sevin E.; Culot M.; Gosselet F.; Staels B.; Deprez B.; Tailleux A.; Charton J.; Beyond the rule of 5: Impact of PEGylation with various polymer sizes on pharmacokinetic properties, structure–properties relationships of mPEGylated small agonists of TGR5 receptor. J Med Chem 2021,64(3),1593-1610
[DOI:
10.1021/acs.jmedchem.0c01774]
Manjili H.K.; Malvandi H.; Mousavi M.S.; Attari E.; Danafar H.; In vitro and in vivo delivery of artemisinin loaded PCL–PEG–PCL micelles and its pharmacokinetic study. Artif Cells Nanomed Biotechnol 2018,46(5),926-936
[DOI:
10.1080/21691401.2017.1347880]
Lu X.; Lu D.; Scully M.; Kakkar V.; The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem 2008,2,57-73
[DOI:
10.1177/1177391X0800200003]
Vogetseder A.; Thies S.; Ingold B.; Roth P.; Weller M.; Schraml P.; Goodman S.L.; Moch H.; αv-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer 2013,133(10),2362-2371
[DOI:
10.1002/ijc.28267]
Bandyopadhyay A.; Raghavan S.; Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009,10(7),645-652
[DOI:
10.2174/138945009788680374]
Kimura R.H.; Teed R.; Hackel B.J.; Pysz M.A.; Chuang C.Z.; Sathirachinda A.; Willmann J.K.; Gambhir S.S.; Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin Cancer Res 2012,18(3),839-849
[DOI:
10.1158/1078-0432.CCR-11-1116]
Hausner S.H.; Abbey C.K.; Bold R.J.; Gagnon M.K.; Marik J.; Marshall J.F.; Stanecki C.E.; Sutcliffe J.L.; Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 2009,69(14),5843-5850
[DOI:
10.1158/0008-5472.CAN-08-4410]
Hausner S.H.; Bauer N.; Hu L.Y.; Knight L.M.; Sutcliffe J.L.; The effect of Bi-Terminal PEGylation of an integrin α v β 6 –Targeted 18 F peptide on pharmacokinetics and tumor uptake. J Nucl Med 2015,56(5),784-790
[DOI:
10.2967/jnumed.114.150680]
Xu J.; Sun T.; Zhong R.; You C.; Tian M.; PEGylation of deferoxamine for improving the stability, cytotoxicity, and iron-overload in an experimental stroke model in rats. Front Bioeng Biotechnol 2020,8,592294
[DOI:
10.3389/fbioe.2020.592294]
Sun J.; Wu J.; Jin H.; Ying T.; Jin W.; Fan M.; Zhou J.; Chen H.; Jin L.; Zhou J.; Structure-guided PEGylated fibroblast growth factor 2 variants accelerate wound healing with improved stability. Authorea 2020,1-18
[DOI:
10.22541/au.158870115.54235041]
Ladwig G.P.; Robson M.C.; Liu R.; Kuhn M.A.; Muir D.F.; Schultz G.S.; Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 2002,10(1),26-37
[DOI:
10.1046/j.1524-475X.2002.10903.x]
Xu H.L.; Chen P.P.; Wang L.F.; Tong M.Q.; Ou Z.; Zhao Y.Z.; Xiao J.; Fu T.L.; Wei-Xue, Skin-permeable liposome improved stability and permeability of bFGF against skin of mice with deep second degree scald to promote hair follicle neogenesis through inhibition of scar formation. Colloids Surf B Biointerfaces 2018,172,573-585
[DOI:
10.1016/j.colsurfb.2018.09.006]
Peng G.; Pan X.; Hu H.; Xu Y.; Wu C.; N-terminal site-specific PEGylation enhances the circulation half-life of Thymosin alpha 1. J Drug Deliv Sci Technol 2019,49,405-412
[DOI:
10.1016/j.jddst.2018.09.009]
Seo H.; Bae H.D.; Pyun H.; Kim B.G.; Lee S.I.; Song J.S.; Lee K.; PEGylation improves the therapeutic potential of dimerized translationally controlled tumor protein blocking peptide in ovalbumin-induced mouse model of airway inflammation. Drug Deliv 2022,29(1),2320-2329
[DOI:
10.1080/10717544.2022.2100511]
Zbyszynski P.; Tomasini-Johansson B.R.; Peters D.M.; Kwon G.S.; Characterization of the PEGylated Functional Upstream Domain Peptide (PEG-FUD): A potent fibronectin assembly inhibitor with potential as an anti-fibrotic therapeutic. Pharm Res 2018,35(7),126
[DOI:
10.1007/s11095-018-2412-7]
Hui Y.F.; Reitz J.; Gemcitabine: A cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997,54(2),162-170
[DOI:
10.1093/ajhp/54.2.162]
Abdalla M.Y.; Ahmad I.M.; Rachagani S.; Banerjee K.; Thompson C.M.; Maurer H.C.; Olive K.P.; Bailey K.L.; Britigan B.E.; Kumar S.; Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Transl Res 2019,207,56-69
[DOI:
10.1016/j.trsl.2018.12.008]
Chiappori A.A.; Rocha-Lima C.M.; New agents in the treatment of small-cell lung cancer: Focus on gemcitabine. Clin Lung Cancer 2003,4(Suppl. 2),S56-S63
[DOI:
10.3816/CLC.2003.s.005]
van Nuland M.; Hillebrand M.J.X.; Rosing H.; Burgers J.A.; Schellens J.H.M.; Beijnen J.H.; Ultra-sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′2′-difluorodeoxyuridine in human plasma for a microdose clinical trial. J Pharm Biomed Anal 2018,151,25-31
[DOI:
10.1016/j.jpba.2017.12.048]
Xu Y.; Keith B.; Grem J.L.; Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004,802(2),263-270
[DOI:
10.1016/j.jchromb.2003.11.038]
Storniolo A.M.; Allerheiligen S.R.; Pearce H.L.; Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997,24(2 Suppl 7),S7-2-S7-7
Robinson K.; Lambiase L.; Li J.; Monteiro C.; Schiff M.; Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003,48(9),1804-1808
[DOI:
10.1023/A]
Yin L.; Ren T.; Zhao S.; Shi M.; Gu J.; Comparative pharmacokinetic study of PEGylated gemcitabine and gemcitabine in rats by LC-MS/MS coupled with pre-column derivatization and MSALL technique. Talanta 2020,206,120184
[DOI:
10.1016/j.talanta.2019.120184]
Liu J.; Zhang Y.; Qu J.; Xu L.; Hou K.; Zhang J.; Qu X.; Liu Y.; β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer 2011,11(1),183
[DOI:
10.1186/1471-2407-11-183]
Wu X.S.; Xie T.; Lin J.; Fan H.Z.; Huang-Fu H.J.; Ni L.F.; Yan H.F.; An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas. J Pharm Pharmacol 2010,61(12),1653-1656
[DOI:
10.1211/jpp.61.12.0010]
Chen M.; Wang S.; Tan M.; Wang Y.; Applications of nanoparticles in herbal medicine: Zedoary turmeric oil and its active compound β-elemene. Am J Chin Med 2011,39(6),1093-1102
[DOI:
10.1142/S0192415X11009421]
Zhai B.; Wu Q.; Wang W.; Zhang M.; Han X.; Li Q.; Chen P.; Chen X.; Huang X.; Li G.; Zhang Q.; Zhang R.; Xiang Y.; Liu S.; Duan T.; Lou J.; Xie T.; Sui X.; Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes. Cancer Biol Med 2020,17(1),60-75
[DOI:
10.20892/j.issn.2095-3941.2019.0156]
Srivastava A.; Brewer A.K.; Mauser-Bunschoten E.P.; Key N.S.; Kitchen S.; Llinas A.; Ludlam C.A.; Mahlangu J.N.; Mulder K.; Poon M.C.; Street A.; Guidelines for the management of hemophilia. Haemophilia 2013,19(1),e1-e47
[DOI:
10.1111/j.1365-2516.2012.02909.x]
Gringeri A.; Lundin B.; Von MacKensen S.; Mantovani L.; Mannucci P.M.; A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011,9(4),700-710
[DOI:
10.1111/j.1538-7836.2011.04214.x]
Manco-Johnson M.J.; Abshire T.C.; Shapiro A.D.; Riske B.; Hacker M.R.; Kilcoyne R.; Ingram J.D.; Manco-Johnson M.L.; Funk S.; Jacobson L.; Valentino L.A.; Hoots W.K.; Buchanan G.R.; DiMichele D.; Recht M.; Brown D.; Leissinger C.; Bleak S.; Cohen A.; Mathew P.; Matsunaga A.; Medeiros D.; Nugent D.; Thomas G.A.; Thompson A.A.; McRedmond K.; Soucie J.M.; Austin H.; Evatt B.L.; Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007,357(6),535-544
[DOI:
10.1056/NEJMoa067659]
Collins P.W.; Blanchette V.S.; Fischer K.; Bjِrkman S.; Oh M.; Fritsch S.; Schroth P.; Spotts G.; Astermark J.; Ewenstein B.; Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009,7(3),413-420
[DOI:
10.1111/j.1538-7836.2008.03270.x]
Mei B.; Pan C.; Jiang H.; Tjandra H.; Strauss J.; Chen Y.; Liu T.; Zhang X.; Severs J.; Newgren J.; Chen J.; Gu J.M.; Subramanyam B.; Fournel M.A.; Pierce G.F.; Murphy J.E.; Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010,116(2),270-279
[DOI:
10.1182/blood-2009-11-254755]
Röstin J.; Smeds A.L.; Åkerblom E.; B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem 2000,11(3),387-396
[DOI:
10.1021/bc990137i]
Shah A.; Solms A.; Wiegmann S.; Ahsman M.; Berntorp E.; Tiede A.; Iorio A.; Mancuso M.E.; Zhivkov T.; Lissitchkov T.; Direct comparison of two extended-half-life recombinant FVIII products: A randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol 2019,98(9),2035-2044
[DOI:
10.1007/s00277-019-03747-2]
Yu J.; Wang Y.; Zhou S.; Li J.; Wang J.; Chi D.; Wang X.; Lin G.; He Z.; Wang Y.; Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy. Acta Pharm Sin B 2020,10(9),1730-1740
[DOI:
10.1016/j.apsb.2020.04.011]
Zhao J.; Du J.; Wang J.; An N.; Zhou K.; Hu X.; Dong Z.; Liu Y.; Folic Acid and Poly(ethylene glycol) decorated paclitaxel nanocrystals exhibit enhanced stability and breast cancer-targeting capability. ACS Appl Mater Interfaces 2021,13(12),14577-14586
[DOI:
10.1021/acsami.1c00184]
Coelho S.C.; Rocha S.; Pereira M.C.; Juzenas P.; Coelho M.A.N.; Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles. J Biomed Nanotechnol 2014,10(4),717-723
[DOI:
10.1166/jbn.2014.1743]
Fischer D.; Li Y.; Ahlemeyer B.; Krieglstein J.; Kissel T.; In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials 2003,24(7),1121-1131
[DOI:
10.1016/S0142-9612(02)00445-3]
Hong S.; Leroueil P.R.; Janus E.K.; Peters J.L.; Kober M.M.; Islam M.T.; Orr B.G.; Baker J.R.; Banaszak Holl M.M.; Interaction of polycationic polymers with supported lipid bilayers and cells: Nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem 2006,17(3),728-734
[DOI:
10.1021/bc060077y]
Sahoo R.K.; Gothwal A.; Rani S.; Nakhate K.T.; Ajazuddin ; Gupta U.; PEGylated dendrimer mediated delivery of bortezomib: Drug conjugation versus encapsulation. Int J Pharm 2020,584,119389
[DOI:
10.1016/j.ijpharm.2020.119389]
Mukherjee S.; Kotcherlakota R.; Haque S.; Bhattacharya D.; Kumar J.M.; Chakravarty S.; Patra C.R.; Improved delivery of doxorubicin using rationally designed PEGylated platinum nanoparticles for the treatment of melanoma. Mater Sci Eng C 2020,108,110375
[DOI:
10.1016/j.msec.2019.110375]
Mukherjee S.; Kotcherlakota R.; Haque S.; Das S.; Nuthi S.; Bhattacharya D.; Madhusudana K.; Chakravarty S.; Sistla R.; Patra C.R.; Silver prussian blue analogue nanoparticles: Rationally designed advanced nanomedicine for multifunctional biomedical applications. ACS Biomater Sci Eng 2020,6(1),690-704
[DOI:
10.1021/acsbiomaterials.9b01693]
Mukherjee S.; Bollu V.S.; Roy A.; Nethi S.K.; Madhusudana K.; Kumar J.M.; Sistla R.; Patra C.R.; Acute toxicity, biodistribution, and pharmacokinetics studies of Pegylated Platinum Nanoparticles in mouse model. Adv NanoBiomed Res 2021,1(7),2000082
[DOI:
10.1002/anbr.202000082]
